Journal
INTERNATIONAL JOURNAL OF CARDIOLOGY
Volume 102, Issue 2, Pages 333-340Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.ijcard.2005.03.075
Keywords
gene expression; giant cell myocarditis; cardiomyopathy; microarray
Categories
Funding
- NHLBI NIH HHS [5R01-HL-065455, 1U01-HL-066583] Funding Source: Medline
Ask authors/readers for more resources
Background: Giant cell myocarditis is a rapidly progressive and often fatal condition without a clear etiology or treatment. A better understanding of giant cell myocarditis pathogenesis is critical to developing treatments to prevent progression and reverse damage. We compared the gene expression of giant cell myocarditis with that of nonfailing hearts. Methods: Left ventricular samples from two giant cell myocarditis patients harvested during ventricular assist device placement and six unused donor hearts were examined using Affymetrix U133A microarrays. Differential gene expression was defined with a Bonferroni-adjusted p value < 0.05 from a Student's t-test and an absolute fold change >= 2.0. Select gene expression was confirmed with quantitative PCR. Results: Of 115 differentially expressed genes, most were upregulated in giant cell myocarditis and involved in immune response, transcriptional regulation, and metabolism. T-cell activation genes included chemokine receptor 4; chemokine ligands 5, 9, 13, and 18; interleukin-10 receptor alpha; and beta-2 integrim. Conclusions: Gene expression analysis of giant cell myocarditis offers novel insights into its pathogenesis, namely the role of T-cell activators of the Th1 subset and immune response genes previously implicated in heart failure. This forms the basis for future work aimed at defining novel therapeutic targets for giant cell myocarditis. (c) 2005 Elsevier Ireland Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available